These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
470 related articles for article (PubMed ID: 27161301)
1. Extracellular microRNAs and endothelial hyperglycaemic memory: a therapeutic opportunity? Prattichizzo F; Giuliani A; De Nigris V; Pujadas G; Ceka A; La Sala L; Genovese S; Testa R; Procopio AD; Olivieri F; Ceriello A Diabetes Obes Metab; 2016 Sep; 18(9):855-67. PubMed ID: 27161301 [TBL] [Abstract][Full Text] [Related]
2. Endothelial Extracellular Vesicles Produced by Senescent Cells: Pathophysiological Role in the Cardiovascular Disease Associated with all Types of Diabetes Mellitus. Carracedo J; Alique M; Ramírez-Carracedo R; Bodega G; Ramírez R Curr Vasc Pharmacol; 2019; 17(5):447-454. PubMed ID: 30124156 [TBL] [Abstract][Full Text] [Related]
3. Extracellular vesicle-shuttled miRNAs: a critical appraisal of their potential as nano-diagnostics and nano-therapeutics in type 2 diabetes mellitus and its cardiovascular complications. Prattichizzo F; Matacchione G; Giuliani A; Sabbatinelli J; Olivieri F; de Candia P; De Nigris V; Ceriello A Theranostics; 2021; 11(3):1031-1045. PubMed ID: 33391519 [TBL] [Abstract][Full Text] [Related]
4. Cellular and molecular mechanisms of endothelial dysfunction in diabetes. Roberts AC; Porter KE Diab Vasc Dis Res; 2013 Nov; 10(6):472-82. PubMed ID: 24002671 [TBL] [Abstract][Full Text] [Related]
5. CD31 Prattichizzo F; De Nigris V; Sabbatinelli J; Giuliani A; Castaño C; Párrizas M; Crespo I; Grimaldi A; Baranzini N; Spiga R; Mancuso E; Rippo MR; Procopio AD; Novials A; Bonfigli AR; Garavelli S; La Sala L; Matarese G; de Candia P; Olivieri F; Ceriello A Diabetes; 2021 Jan; 70(1):240-254. PubMed ID: 33097483 [TBL] [Abstract][Full Text] [Related]
6. Extracellular Vesicles and Insulin Resistance: A Potential Interaction in Vascular Dysfunction. Sáez T; Toledo F; Sobrevia L Curr Vasc Pharmacol; 2019; 17(5):491-497. PubMed ID: 30277159 [TBL] [Abstract][Full Text] [Related]
11. Therapeutic Potentials of Extracellular Vesicles for the Treatment of Diabetes and Diabetic Complications. Hu W; Song X; Yu H; Sun J; Zhao Y Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708290 [TBL] [Abstract][Full Text] [Related]
12. Can Epigenetics of Endothelial Dysfunction Represent the Key to Precision Medicine in Type 2 Diabetes Mellitus? Coco C; Sgarra L; Potenza MA; Nacci C; Pasculli B; Barbano R; Parrella P; Montagnani M Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31212911 [TBL] [Abstract][Full Text] [Related]
13. No detectable differential microRNA expression between non-atherosclerotic arteries of type 2 diabetic patients (treated or untreated with metformin) and non-diabetic patients. Steffensen LB; Feddersen S; Preil SR; Rasmussen LM Cardiovasc Diabetol; 2018 May; 17(1):72. PubMed ID: 29773082 [TBL] [Abstract][Full Text] [Related]
14. Endothelial dysfunction and its role in diabetic vascular disease. Hartge MM; Kintscher U; Unger T Endocrinol Metab Clin North Am; 2006 Sep; 35(3):551-60, viii-ix. PubMed ID: 16959585 [TBL] [Abstract][Full Text] [Related]
15. Endothelial dysfunction and type 2 diabetes. Part 2: altered endothelial function and the effects of treatments in type 2 diabetes mellitus. Guerci B; Böhme P; Kearney-Schwartz A; Zannad F; Drouin P Diabetes Metab; 2001 Sep; 27(4 Pt 1):436-47. PubMed ID: 11547217 [TBL] [Abstract][Full Text] [Related]
16. Macro- and microvascular endothelial dysfunction in diabetes. Shi Y; Vanhoutte PM J Diabetes; 2017 May; 9(5):434-449. PubMed ID: 28044409 [TBL] [Abstract][Full Text] [Related]
17. Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes. Lund SS; Tarnow L; Stehouwer CD; Schalkwijk CG; Teerlink T; Gram J; Winther K; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag AA Eur J Endocrinol; 2008 May; 158(5):631-41. PubMed ID: 18426821 [TBL] [Abstract][Full Text] [Related]
18. Vascular endothelium as a target of beraprost sodium and fenofibrate for antiatherosclerotic therapy in type 2 diabetes mellitus. Otsuki M; Goya K; Kasayama S Vasc Health Risk Manag; 2005; 1(3):209-15. PubMed ID: 17319106 [TBL] [Abstract][Full Text] [Related]
19. "Inflammaging" as a Druggable Target: A Senescence-Associated Secretory Phenotype-Centered View of Type 2 Diabetes. Prattichizzo F; De Nigris V; La Sala L; Procopio AD; Olivieri F; Ceriello A Oxid Med Cell Longev; 2016; 2016():1810327. PubMed ID: 27340505 [TBL] [Abstract][Full Text] [Related]
20. The vascular smooth muscle cell: a therapeutic target in Type 2 diabetes? Porter KE; Riches K Clin Sci (Lond); 2013 Aug; 125(4):167-82. PubMed ID: 23634936 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]